Ganoderic acid loaded nano-lipidic carriers improvise treatment of hepatocellular carcinoma.
Animals
Antineoplastic Agents
/ administration & dosage
Antioxidants
/ metabolism
Carrier Proteins
/ antagonists & inhibitors
Drug Carriers
/ chemistry
Drug Liberation
Drug Stability
Hep G2 Cells
Humans
Lipids
/ chemistry
Liver
/ metabolism
Liver Neoplasms, Experimental
/ drug therapy
Molecular Docking Simulation
NF-kappa B
/ antagonists & inhibitors
Nanoparticles
/ ultrastructure
Proto-Oncogene Proteins c-akt
/ antagonists & inhibitors
Proto-Oncogene Proteins c-bcl-2
/ antagonists & inhibitors
Rats, Wistar
STAT3 Transcription Factor
/ antagonists & inhibitors
Signal Transduction
/ drug effects
Triterpenes
/ administration & dosage
Akt/PKB
Ganoderic acid
HepG2 cell
antioxidant
antioxidants enzymes
entrapment efficiency
hepatoprotective
nano-lipid carrier
Journal
Drug delivery
ISSN: 1521-0464
Titre abrégé: Drug Deliv
Pays: England
ID NLM: 9417471
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
31
7
2019
pubmed:
31
7
2019
medline:
15
2
2020
Statut:
ppublish
Résumé
This work evaluates nano-lipid carrier of ganoderic acid (GA) and molecular docking on various cancer signaling pathways, an attempt to improve the hepatic condition associated with hepatic carcinoma (HCC) induced by diethyl-nitrosamine (DEN) in Wistar rats. Molecular docking mechanism of GA was performed through binding simulation analysis for various cancer signaling pathway, viz., Bcl-2, Pl3K, NF-κB, Akt/PKB, and Stat-3. Double emulsion solvent displacement method was implied for preparation of GA-loaded nano-lipid carrier. GA-NLCs were evaluated for drug loading capacity, entrapment efficiency, particle size, gastric stability,
Identifiants
pubmed: 31357897
doi: 10.1080/10717544.2019.1606865
pmc: PMC6711158
doi:
Substances chimiques
Antineoplastic Agents
0
Antioxidants
0
Carrier Proteins
0
Drug Carriers
0
Lipids
0
NF-kappa B
0
PI3KAP protein, rat
0
Proto-Oncogene Proteins c-bcl-2
0
STAT3 Transcription Factor
0
Triterpenes
0
ganoderic acid
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
782-793Références
Nat Genet. 2002 Aug;31(4):339-46
pubmed: 12149612
Int J Pharm. 2002 Aug 21;242(1-2):121-8
pubmed: 12176234
Adv Drug Deliv Rev. 2002 Nov 1;54 Suppl 1:S131-55
pubmed: 12460720
Anticancer Res. 2002 Nov-Dec;22(6A):3309-18
pubmed: 12530080
Pharmacol Toxicol. 2003 Jan;92(1):33-8
pubmed: 12710595
Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16
pubmed: 15508102
Acta Pharmacol Sin. 2004 Nov;25(11):1387-95
pubmed: 15525457
Chem Biol Interact. 2006 Mar 10;160(1):1-40
pubmed: 16430879
Alcohol Alcohol. 2006 Sep-Oct;41(5):528-33
pubmed: 16799164
J Hepatol. 2006 Oct;45(4):529-38
pubmed: 16879891
Int Immunopharmacol. 2007 Jun;7(6):864-70
pubmed: 17466920
Free Radic Biol Med. 2007 Oct 15;43(8):1109-20
pubmed: 17854706
Pharmazie. 2007 Oct;62(10):790-7
pubmed: 18236787
Hepatology. 2008 Apr;47(4):1363-70
pubmed: 18366115
Clin Cancer Res. 2009 Feb 15;15(4):1126-32
pubmed: 19228717
Exp Toxicol Pathol. 2010 Mar;62(2):171-81
pubmed: 19409769
J Agric Food Chem. 2009 Jun 10;57(11):5049-57
pubmed: 19422227
Cancer Genomics Proteomics. 2009 Sep-Oct;6(5):263-8
pubmed: 19996131
Int J Pharm. 2011 Jul 29;414(1-2):267-75
pubmed: 21596122
Mol Cell Biochem. 2012 Jan;360(1-2):51-60
pubmed: 21879312
PLoS One. 2012;7(10):e47687
pubmed: 23112834
Pharm Res. 2014 Apr;31(4):946-58
pubmed: 24135934
Nanomedicine. 2014 Jul;10(5):959-69
pubmed: 24407148
Metabolism. 2014 Jun;63(6):773-82
pubmed: 24726813
Drug Deliv. 2016;23(1):214-29
pubmed: 24825490
Liver Int. 2015 May;35(5):1590-6
pubmed: 24836705
Curr Biol. 2014 May 19;24(10):R453-62
pubmed: 24845678
Oxid Med Cell Longev. 2014;2014:360438
pubmed: 24999379
Expert Opin Drug Deliv. 2014 Dec;11(12):1833-47
pubmed: 25078031
Drug Dev Ind Pharm. 2015;41(8):1368-75
pubmed: 25151872
Colloids Surf B Biointerfaces. 2015 Feb 1;126:87-97
pubmed: 25543986
Phytochemistry. 2015 Jun;114:56-65
pubmed: 25794896
Acta Biomater. 2015 Sep;24:140-51
pubmed: 26116986
J Drug Target. 2016;24(2):147-60
pubmed: 26204326
Int J Pharm. 2015 Sep 30;493(1-2):466-82
pubmed: 26211900
Nanomedicine. 2016 Oct;12(7):2043-2060
pubmed: 27234306
Inflammopharmacology. 2017 Feb;25(1):159-175
pubmed: 28155120
Pharm Biol. 2017 Dec;55(1):1458-1466
pubmed: 28345375
Inflammopharmacology. 2018 Feb;26(1):133-146
pubmed: 28608141
Biomed Pharmacother. 2017 Oct;94:834-842
pubmed: 28802237
Int J Nanomedicine. 2017 Sep 11;12:6747-6758
pubmed: 28932118
Eur J Pharm Sci. 2018 Mar 30;115:119-125
pubmed: 29248559
Nanomedicine (Lond). 2018 Apr;13(8):849-870
pubmed: 29565220
Environ Sci Pollut Res Int. 2018 Jul;25(20):20057-20070
pubmed: 29748795
J Microencapsul. 2018 Jun;35(4):327-343
pubmed: 29873288
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1237-48
pubmed: 7713785